Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Psilocybin therapy Clear all
Completed Phase 2 Interventional Results available

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

NCT04739865
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 25, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers

NCT05220046
View directory record Official record
Conditions
Pancreas Cancer, Biliary Tract Cancer, Psychological Distress, Gastrointestinal Cancer
Interventions
Psilocybin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Psilocybin Administration With 5-HT1a Blockade

NCT07565493
View directory record Official record
Conditions
Psychedelic Effects in Healthy Volunteers
Interventions
Pindolol, Placebo, Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Recruiting Phase 2 Interventional

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT07610369
View directory record Official record
Conditions
Depression, Parkinson's Disease (PD)
Interventions
Psilocybin (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Completed Not applicable Interventional

Low-Income Group Psilocybin Assisted Therapy for Depression

NCT06372197
View directory record Official record
Conditions
Depression
Interventions
Psilocybin
Drug
Lead sponsor
Matthew Hicks
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 25, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain

NCT05506982
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Psilocybin, Psychotherapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
26 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 25, 2026, 8:24 PM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

NCT06200155
View directory record Official record
Conditions
Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer
Interventions
Psilocybin, Niacin
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Psilocybin for Treatment of OCD-2

NCT06992999
View directory record Official record
Conditions
Obsessive - Compulsive Disorder
Interventions
Low Dose Psilocybin, High Dose Psilocybin
Drug
Lead sponsor
Francisco A Moreno
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

NCT07306364
View directory record Official record
Conditions
Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin
Interventions
Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Active, not recruiting Phase 1 Interventional

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

NCT03554174
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low Dose Psilocybin, Placebo, Medium Dose Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 25, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of Psilocybin for Major Depressive Disorder (MDD)

NCT03866174
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin, Niacin, Set and Setting (SaS) Protocol
Drug · Other
Lead sponsor
Usona Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
San Francisco, California • Santa Monica, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Not yet recruiting Phase 2 Interventional

Group PACBT for Depression

NCT07566104
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Psilocybin, Cognitive Behavioral Therapy
Interventions
Psilocybin (drug), Group Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Recruiting Phase 1 Interventional

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

NCT07053917
View directory record Official record
Conditions
Stroke, Chronic Stroke, Intracerebral Haemorrhage, Intracerebral Haemorrhage (ICH), Intracerebral Hemorrhage Basal Ganglia, Ischemic Stroke, Ischemic Stroke and Hemorrhagic Stroke, Hemiparesis After Stroke, Hemiplegia Following Ischemic Stroke, Hemiplegia and Hemiparesis, Hemiplegia and/or Hemiparesis Following Stroke, Middle Cerebral Artery Stroke
Interventions
Psilocybin (Usona Institute)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

NCT01943994
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 25, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

Effects of Psilocybin in Post-Treatment Lyme Disease

NCT05305105
View directory record Official record
Conditions
Post-Treatment Lyme Disease, Chronic Lyme Disease, Lyme Disease, Chronic
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 25, 2026, 8:24 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

NCT05624268
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
40
States / cities
Tuscon, Arizona • Culver City, California • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Completed Phase 2 Interventional

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

NCT04661514
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Psilocybin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Sep 25, 2026, 8:24 PM EDT
Active, not recruiting Phase 2 Interventional

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

NCT07336238
View directory record Official record
Conditions
Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Psychotherapy, Psilocybin, Survey Administration
Behavioral · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Completed Phase 1 Interventional

PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout

NCT05557643
View directory record Official record
Conditions
Depression, Burnout, Professional
Interventions
Psilocybin, Mindfulness-Based Stress Reduction (MBSR)
Drug · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
25 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 25, 2026, 8:24 PM EDT
Completed Phase 2 Interventional Results available

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

NCT02061293
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Psilocybin, Diphenhydramine, Motivational Enhancement and Taking Action (META)
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
25 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Albuquerque, New Mexico • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 25, 2026, 8:24 PM EDT
Active, not recruiting Phase 2 Interventional

Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT04410913
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Psilocybin plus Visual Healing Set and Setting, Psilocybin plus Standard Set and Setting
Drug
Lead sponsor
Keith Heinzerling
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 25, 2026, 8:24 PM EDT
Recruiting Phase 2 Interventional

Psilocybin in Cancer Pain Study

NCT06001749
View directory record Official record
Conditions
Opioid-Related Disorders, Pain Management, Pain Management and Care, Advanced Cancer, Advanced Cancers
Interventions
Psilocybin
Drug
Lead sponsor
Yvan Beaussant, MD, MSci
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy

NCT07332143
View directory record Official record
Conditions
PTSD
Interventions
psilocybin, Supportive Therapy, Prolonged Exposure Therapy
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 25, 2026, 8:24 PM EDT
Not yet recruiting Phase 2 Interventional

Study of Psilocybin Under Anesthesia Controlled by EEG

NCT07479550
View directory record Official record
Conditions
Major Depression
Interventions
Psilocybin (Usona Institute), Propofol, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 8:24 PM EDT